Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report

IF 0.9 Q4 HEMATOLOGY
Tiffany Nong , Xiaoqiong Wang , Wenhui Li , Ellen Madarang , Justin Watts , Justin Taylor
{"title":"Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report","authors":"Tiffany Nong ,&nbsp;Xiaoqiong Wang ,&nbsp;Wenhui Li ,&nbsp;Ellen Madarang ,&nbsp;Justin Watts ,&nbsp;Justin Taylor","doi":"10.1016/j.lrr.2025.100535","DOIUrl":null,"url":null,"abstract":"<div><div>Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoma that is highly responsive to the purine analog cladribine. A defining feature of classical HCL is the presence of the BRAF V600E mutation, which is almost universally present. The transformation of HCL to an aggressive large B-cell lymphoma is extremely rare. Here, we report a case of intercurrent presentation of worsening classical HCL with a rapidly evolving BRAF V600E-negative aggressive large B-cell lymphoma and associated hemophagocytic lymphohistiocytosis (HLH). The contiguous presentation of these three entities posed significant diagnostic and therapeutic challenges. Despite treatment with cladribine, the patient’s condition deteriorated, leading to a palliative focus. This case underscores the challenges of managing multiple intercurrent hematologic malignancies manifesting with overlapping symptoms and sites of organ involvement but non-overlapping treatments. The presence of HLH as a complication in patients with malignancy further complicates the clinical picture and requires early recognition and prompt intervention. Further research is needed to better understand the pathophysiological links between HCL, large cell transformation, and HLH. Additionally, registry or other cross-sectional studies with larger numbers of HCL patients could clarify the exact frequency of these rare but fatal complications.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100535"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048925000378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoma that is highly responsive to the purine analog cladribine. A defining feature of classical HCL is the presence of the BRAF V600E mutation, which is almost universally present. The transformation of HCL to an aggressive large B-cell lymphoma is extremely rare. Here, we report a case of intercurrent presentation of worsening classical HCL with a rapidly evolving BRAF V600E-negative aggressive large B-cell lymphoma and associated hemophagocytic lymphohistiocytosis (HLH). The contiguous presentation of these three entities posed significant diagnostic and therapeutic challenges. Despite treatment with cladribine, the patient’s condition deteriorated, leading to a palliative focus. This case underscores the challenges of managing multiple intercurrent hematologic malignancies manifesting with overlapping symptoms and sites of organ involvement but non-overlapping treatments. The presence of HLH as a complication in patients with malignancy further complicates the clinical picture and requires early recognition and prompt intervention. Further research is needed to better understand the pathophysiological links between HCL, large cell transformation, and HLH. Additionally, registry or other cross-sectional studies with larger numbers of HCL patients could clarify the exact frequency of these rare but fatal complications.
毛细胞白血病和弥漫性大b细胞淋巴瘤并发噬血细胞性淋巴组织细胞增多症1例
毛细胞白血病(HCL)是一种罕见的惰性b细胞淋巴瘤,对嘌呤类似物克拉德里滨高度敏感。经典HCL的一个决定性特征是BRAF V600E突变的存在,这种突变几乎普遍存在。HCL向侵袭性大b细胞淋巴瘤的转变极为罕见。在这里,我们报告了一例恶化的经典HCL与快速发展的BRAF v600e阴性侵袭性大b细胞淋巴瘤和相关的噬血细胞性淋巴组织细胞增多症(HLH)并存的病例。这三种实体的连续表现构成了重大的诊断和治疗挑战。尽管用克拉宾治疗,病人的病情恶化,导致姑息治疗的焦点。本病例强调了管理多重并发的血液恶性肿瘤的挑战,表现为重叠的症状和器官受累部位,但不重叠的治疗。作为恶性肿瘤患者的并发症,HLH的存在进一步使临床情况复杂化,需要早期识别和及时干预。需要进一步的研究来更好地了解HCL、大细胞转化和HLH之间的病理生理联系。此外,大量HCL患者的登记或其他横断面研究可以明确这些罕见但致命的并发症的确切频率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信